Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson; Sisse R Ostrowski

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Research output: Contribution to journal › Journal article › Research › peer-review

11 Citations (Scopus)

Abstract

Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

Original language	English
Journal	Drug Design, Development and Therapy
Volume	4
Pages (from-to)	107-16
Number of pages	10
ISSN	1177-8881
Publication status	Published - 1 Jan 2010

Cite this

@article{b3ddaee0f5914f62a7917554109582c3,

title = "Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders",

abstract = "Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.",

author = "Johansson, {P{\"a}r I} and Ostrowski, {Sisse R}",

year = "2010",

month = jan,

day = "1",

language = "English",

volume = "4",

pages = "107--16",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

AU - Johansson, Pär I

AU - Ostrowski, Sisse R

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

AB - Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

M3 - Journal article

SN - 1177-8881

VL - 4

SP - 107

EP - 116

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

ER -